Sirijatuphat, 93 patient favipiravir early treatment RCT: 64% faster improvement [p=0.0005], 43% lower progression [p=0.25], and 4% worse viral clearance [p=0.87] https://c19p.org/sirijatuphat2
copied to clipboard
Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study
et al., medRxiv, doi:10.1101/2022.06.06.22275902, TCTR20200514001
RCT 93 patients in Thailand showing significantly faster clinical improvement with favipiravir treatment. 1800mg favipiravir bid day 1, 800mg bid 5-14 days until PCR-.
|
time to clinical improvement, 63.9% lower, HR 0.36, p < 0.001, treatment 62, control 31, inverted to make RR<1 favor treatment, primary outcome.
|
|
clinical improvement, 89.9% lower, OR 0.10, p < 0.001, treatment 62, control 31, inverted to make OR<1 favor treatment, logistic regression, day 14, RR approximated with OR.
|
|
risk of mild pneumonia, 42.9% lower, RR 0.57, p = 0.25, treatment 8 of 62 (12.9%), control 7 of 31 (22.6%), NNT 10.
|
|
risk of no viral clearance, 4.2% higher, HR 1.04, p = 0.87, treatment 62, control 31, adjusted per study, inverted to make RR<1 favor treatment.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Sirijatuphat et al., 8 Jun 2022, Randomized Controlled Trial, Thailand, peer-reviewed, 9 authors, trial TCTR20200514001.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.